AbbVie Inc. (NYSE:ABBV) may not have been too far off the mark when it claimed a Humira biosimilar is unlikely to reach markets before at least 2022. http://www.bidnessetc.com/61315-amgen-loses-out-on-humira-abbvie-growth-plans-intact/